Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results, Beats Estimates By $0.37 EPS

Protara Therapeutics (NASDAQ:TARA) posted its earnings results on Tuesday. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.37, Zacks reports.

Protara Therapeutics Stock Performance

Shares of TARA stock remained flat at $1.90 during mid-day trading on Thursday. 107,992 shares of the company’s stock traded hands, compared to its average volume of 233,772. The stock has a market capitalization of $39.12 million, a PE ratio of -0.51 and a beta of 1.85. Protara Therapeutics has a 1-year low of $1.04 and a 1-year high of $5.24. The stock’s 50-day moving average price is $2.34 and its two-hundred day moving average price is $2.99.

Insiders Place Their Bets

In other news, major shareholder Opaleye Management Inc. sold 11,396 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $2.44, for a total transaction of $27,806.24. Following the transaction, the insider now owns 56,500 shares in the company, valued at $137,860. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 248,588 shares of company stock valued at $671,847. 12.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts recently weighed in on TARA shares. Oppenheimer increased their price target on Protara Therapeutics from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Monday, April 22nd. HC Wainwright reiterated a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a report on Thursday.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.